Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rilzabrutinib in IgG4-Related Disease
NCT04520451Phase 2Completed
- Sponsor
- Sanofi
- Start
- Aug 2020
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 2 trial of rilzabrutinib in IgG4-related disease (IgG4-RD), sponsored by Sanofi. Started Aug 2020; status: completed.
02
Drugs
rilzabrutinib
03
Conditions
IgG4-related disease (IgG4-RD)
Beyond the preview
Go deeper on NCT04520451.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04520451.